|
Hope Medicine Announces US FDA Clearance for Phase II Clinical Trial of A First-in-class Monoclonal Antibody, HMI-115, in Androgen Alopecia
|
SHANGHAI, Jan. 26, 2022 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical stage innovative biopharmaceutical company, has recently announced that U.S. Food and Drug Administration (FDA) has approved its Invest...
Full "IntellAsia: Resources" article
|
|